Semaglutide Cuts Risk of Developing Diabetic Kidney Disease Nearly in Half in High-Risk Patients

Semaglutide reduced the odds of developing new diabetic kidney disease by 44% overall (OR 0.56, p<0.0001) and 49% in high-risk patients (OR 0.51), with NNT of 7 in the high-risk population, primarily by reducing urinary albumin excretion.

Post hoc analysis of the SUSTAIN 6 randomized, double-blind, placebo-controlled trial. Included 1,139 participants with T2D without DKD at baseline. Stratified by validated DKD risk model. Primary outcome: development of DKD (UACR ≥30 mg/g and/or eGFR decline). Compared semaglutide 0.5/1.0 mg vs. placebo.

Diabetic kidney disease leads to dialysis for millions of people worldwide and is the leading cause of kidney failure. Finding that semaglutide — already widely prescribed for diabetes and weight loss — can nearly halve the risk of developing DKD means a drug many patients are already taking could protect their kidneys too, potentially preventing years of dialysis.

This finding adds kidney protection to semaglutide's growing list of benefits beyond blood sugar control, joining cardiovascular risk reduction and weight loss. If confirmed in prospective trials, semaglutide could become a cornerstone of DKD prevention — particularly significant since GLP-1 agonists are increasingly prescribed as first-line diabetes treatments. The NNT of 7 makes a powerful case for early intervention in high-risk patients.

Post hoc analysis — not a pre-specified trial endpoint, so results need confirmation in prospective studies. The DKD risk model classification may not capture all relevant patient differences. SUSTAIN 6 was not designed or powered to assess DKD prevention specifically. The analysis doesn't distinguish between semaglutide's direct kidney effects and indirect effects through blood sugar and weight reduction.